BioCryst Pharmaceuticals Inc (BCRX) — Analysis Summary
BioCryst Pharmaceuticals Inc (BCRX) has a market cap of $2.06B with year-over-year revenue growth of +94.1%. Net margin stands at 30.2%. The stock trades at a P/E ratio of -5.4.
Key Takeaways
- Revenue changed +94.1% year-over-year
- Net margin of 30.2%
- P/E ratio of -5.4
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, BCRX posted revenue growth of +94.1% and trades at a P/E of -5.4.
BioCryst Pharmaceuticals Inc (BCRX)
PREVIOUS CLOSE 2026-10-13 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -4.2x — earnings do not cover interest payments
Net income turned negative after a profitable prior period.
Shareholder equity is negative, which can signal balance-sheet stress.
Operating margin at -33.3% — material operating losses
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
435
Headquarters
DURHAM, NC
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.